For years, home growers prized a potent magic mushroom called Natal Super Strength. Nobody had ever named it. New DNA work shows it is a separate species, and its family tree pushes the origins of the world's favorite psychedelic mushroom back more than a million years.
What if the trip was never the point? A new class of compounds promises the brain-rewiring of psychedelics without the hallucination, and the first non-tripping antidepressant is heading for trials you can run from your own couch.
Scientists finally caught the munchies in the act. A new study shows cannabis turns up the brain's reward for food, spikes the hunger hormone, and sharpens taste. The same circuit could feed people who can't eat.
Psychedelic science spent sixty years studying the young. A new UC Berkeley study finally hands the eye mask to people between 60 and 85 — and asks whether an old brain can still change its mind.
Psilocybin makes a magic mushroom magic. A new study shows two unrelated mushroom groups evolved it separately, by completely different chemical routes that meet only near the finish. Which raises the question decades of human fascination still can't answer: what is psilocybin actually for?
A lab in Israel engineered one tobacco plant to make psilocybin, DMT, bufotenin, 5-MeO-DMT, and psilocin at once. The molecules just left the mushroom and the toad behind. What that means for cost, supply, and a drug law written when the drug and its source were the same thing.
Jaguars roll in the ayahuasca vine. Reindeer hunt psychedelic mushrooms in the snow. Wallabies leave crop circles in Tasmania's poppy fields. The urge to get high isn't uniquely human — one researcher called it a fourth drive, as deep as hunger and thirst.
Last fall Congress redefined hemp and capped legal products at 0.4 milligrams of THC. The rule erases an estimated 95 percent of the market by November. Now the same White House that signed it is asking Congress to carve out an exception before the deadline it created.
The FDA lost its commissioner in May. Four weeks from now, the agency is supposed to help decide whether all marijuana moves to Schedule III. The most powerful job in American drug policy is being done by a caretaker, and almost nobody is talking about it.
People are searching for "microdose therapy for chronic inflammation" and finding wellness sites that promise more than the science can back. Psychedelics show real anti-inflammatory promise in the lab. Whether a microdose delivers it in a human body is a different, much shakier question.
A London lab gave 34 depressed people a single IV dose of DMT, the compound in ayahuasca, and saw depression scores fall for up to six months. No ceremony, no all-night vigil, no nausea. Just the molecule. Which raises a question the trial can't answer: how much was ever the chemical alone?
In April, the DOJ rescheduled medical cannabis to Schedule III — handing operators billions in tax relief. It opened zero prison cells. Now 29 members of Congress want Trump to commute the sentences of roughly 3,000 people still serving federal time for a drug the government just reclassified.